Trial News & Events

Longitudinal Assessment of the Gut Microbiome in People with ALS

The Neurological Clinical Research Institute at Massachusetts General Hospital is seeking individuals to participate in a Longitudinal Assessment of the Gut Microbiome in People with ALS research study currently enrolling under the direction of Dr. James Berry.

Pathogenesis in C9Orf72-Related ALS (Picals)

The Emory ALS Center is looking for adults who are 18 years and older who are at risk for getting diagnosed with C9 ALS in the future.

"AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS," published by AI Therapeutics

AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation of a Phase II study for a promising new approach to treat amyotrophic lateral sclerosis (ALS).

Laying the Foundation for a Collaborative Future in ALS Research

Prilenia and Ferrer Announce FDA Clearance to Start the “PREVAiLS” Pivotal Phase 3 Study with Pridopidine in ALS